Zuanetti G, Neilson J M, Latini R, Santoro E, Maggioni A P, Ewing D J
University Department of Medicine, Royal Infirmary, Edinburgh, Scotland.
Circulation. 1996 Aug 1;94(3):432-6. doi: 10.1161/01.cir.94.3.432.
Studies performed before the introduction of fibrinolysis showed that a low heart rate variability (HRV) is associated with higher mortality in post-myocardial infarction (MI) patients. We evaluated whether HRV adds information relevant to risk stratification in patients treated with fibrinolysis as well.
From 24-hour ECG recordings obtained at discharge in patients treated with recombinant tissue-type plasminogen activator or streptokinase, we measured several time-domain indexes of HRV: standard deviation (SDNN), root-mean-square of successive differences (RMSSD), and number of RR interval increases > 50 ms ("NN50+"). The prognostic value of HRV for total and cardiovascular mortality was assessed. Of 567 patients with valid recordings, 52 (9.1%) died during the 1000 days of follow-up, 44 (7.8%) of cardiovascular causes. All indexes of low HRV were able to identify patients (16% to 18% of total population) with a higher total mortality (20.8% to 24.2% versus 6.0% to 6.8%, depending on index used). The independent predictive value of low HRV was confirmed by the adjusted analysis with the following relative risks: NN50+, 3.5 (95% CI, 1.9 to 6.7); SDNN, 3.0 (95% CI, 1.55 to 5.9); and RMSSD, 2.8 (95% CI, 1.5 to 5.3). Advanced age, previous MI, Killip class at entry, and use of digitalis were also independent predictors. Similar data were obtained for cardiovascular mortality.
Time-domain indexes of HRV retain their independent prognostic significance even in post-MI patients of all ages treated with fibrinolysis.
在纤维蛋白溶解疗法应用之前所进行的研究表明,心率变异性(HRV)降低与心肌梗死(MI)后患者的较高死亡率相关。我们还评估了HRV是否能为接受纤维蛋白溶解疗法治疗的患者的风险分层提供相关信息。
从接受重组组织型纤溶酶原激活剂或链激酶治疗的患者出院时获取的24小时心电图记录中,我们测量了HRV的几个时域指标:标准差(SDNN)、逐次差值的均方根(RMSSD)以及RR间期增加>50毫秒的次数(“NN50+”)。评估了HRV对总死亡率和心血管死亡率的预后价值。在567例有有效记录的患者中,52例(9.1%)在1000天的随访期间死亡,44例(7.8%)死于心血管原因。所有低HRV指标都能够识别出总死亡率较高的患者(占总人口的16%至18%)(根据所使用的指标,死亡率为20.8%至24.2%,而其他患者为6.0%至6.8%)。通过调整分析,低HRV的独立预测价值得到证实,相对风险如下:NN50+,3.5(95%CI,1.9至6.7);SDNN,3.0(95%CI,1.55至5.9);RMSSD,2.8(95%CI,1.5至5.3)。高龄、既往心肌梗死、入院时的Killip分级以及洋地黄的使用也是独立的预测因素。心血管死亡率也得到了类似的数据。
即使在接受纤维蛋白溶解疗法治疗的各年龄段心肌梗死后患者中,HRV的时域指标仍保留其独立的预后意义。